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Objectives We examined mortality in relation to coronary artery disease (CAD) as assessed by 64-detector row coronary
computed tomography angiography (CCTA).
Background Although CCTA has demonstrated high diagnostic performance for detection and exclusion of obstructive CAD,
the prognostic findings of CAD by CCTA have not, to date, been examined for age- and sex-specific outcomes.
Methods We evaluated a consecutive cohort of 24,775 patients undergoing 64-detector row CCTA between 2005 and
2009 without known CAD who met inclusion criteria. In these patients, CAD by CCTA was defined as none (0%
stenosis), mild (1% to 49% stenosis), moderate (50% to 69% stenosis), or severe (70% stenosis). CAD severity
was judged on a per-patient, per-vessel, and per-segment basis. Time to mortality was estimated using multivari-
able Cox proportional hazards models.
Results At a 2.3  1.1-year follow-up, 404 deaths had occurred. In risk-adjusted analysis, both per-patient obstructive
(hazard ratio [HR]: 2.60; 95% confidence interval [CI]: 1.94 to 3.49; p  0.0001) and nonobstructive (HR: 1.60;
95% CI: 1.18 to 2.16; p  0.002) CAD conferred increased risk of mortality compared with patients without evi-
dent CAD. Incident mortality was associated with a dose-response relationship to the number of coronary ves-
sels exhibiting obstructive CAD, with increasing risk observed for nonobstructive (HR: 1.62; 95% CI: 1.20 to 2.19;
p  0.002), obstructive 1-vessel (HR: 2.00; 95% CI: 1.43 to 2.82; p  0.0001), 2-vessel (HR: 2.92; 95% CI: 2.00
to 4.25; p  0.0001), or 3-vessel or left main (HR: 3.70; 95% CI: 2.58 to 5.29; p  0.0001) CAD. Importantly,
the absence of CAD by CCTA was associated with a low rate of incident death (annualized death rate: 0.28%).
When stratified by age 65 years versus 65 years, younger patients experienced higher hazards for death for
2-vessel (HR: 4.00; 95% CI: 2.16 to 7.40; p  0.0001 vs. HR: 2.46; 95% CI: 1.51 to 4.02; p  0.0003) and
3-vessel (HR: 6.19; 95% CI: 3.43 to 11.2; p  0.0001 vs. HR: 3.10; 95% CI: 1.95 to 4.92; p  0.0001) CAD. The
relative hazard for 3-vessel CAD (HR: 4.21; 95% CI: 2.47 to 7.18; p  0.0001 vs. HR: 3.27; 95% CI: 1.96 to
5.45; p  0.0001) was higher for women as compared with men.
Conclusions Among individuals without known CAD, nonobstructive and obstructive CAD by CCTA are associated with higher
rates of mortality, with risk profiles differing for age and sex. Importantly, absence of CAD is associated with a
very favorable prognosis. (J Am Coll Cardiol 2011;58:849–60) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.074
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Age- and Sex-Related Prognosis by CCTA August 16, 2011:849–60Coronary computed tomography
angiography (CCTA) is a re-
cently introduced noninvasive
imaging modality that permits
accurate detection and exclusion
of coronary artery disease (CAD)
(1–3). Prior studies have exam-
ined the prognostic significance
of CAD detection by CCTA,
but have been generally limited
to single centers and small co-
horts (4–14). Given the enor-
mous evidence base on prognosis
with other cardiac imaging mo-
dalities, the development of “real
world” effectiveness data that are
acquired across diverse health-
care settings and populations is a
requisite criterion to guide ap-
propriate application of CCTA.
Fundamental to the use of
See page 861
CCTA is its ability to risk stratify younger and older women
and men. To date, however, age- and sex-specific outcomes
of CCTA-identified CAD have been absent or exploratory
(15). To that end, we examined the predictive value of
nonobstructive and obstructive CAD from a large cohort of
23,854 patients without known CAD for intermediate-term
mortality risk and further investigated the relationship of
mortality risk to CAD as stratified by age and sex.
Methods
Patients. CONFIRM (Coronary CT Angiography Evalu-
ation for Clinical Outcomes: An International Multicenter
Registry) enrolled consecutive adults 18 years of age
between 2005 and 2009 who underwent 64-detector row
CCTA for suspected CAD at 12 centers (Cedars Sinai
Medical Center, Los Angeles, California; Harbor UCLA
Medical Center, Los Angeles, California; Tennessee Heart
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of Imaging, Cedars Sinai Medical Center, Los Angeles, California; §§William
Beaumont Hospital, Royal Oaks, Michigan;  Department of Medicine and Radi-
logy, University of Ottawa, Ontario, Canada; ¶¶Capitol Cardiology Associates,
lbany, New York; ##Division of Cardiology, Deutsches Herzzentrum Munchen,
unich, Germany; ***University Hospital, Zurich, Switzerland; †††Department of
Abbreviations
and Acronyms
CAD  coronary artery
disease
CCTA  coronary
computed tomography
angiography
CI  confidence interval
CT  computed
tomography
D-F  Diamond-Forrester
HR  hazard ratio
LAD  left anterior
descending artery
LCx  left circumflex
artery
LM  left main artery
RCA  right coronary
arteryedicine, Emory University School of Medicine, Atlanta, Georgia; and the ‡‡‡Depart-
ent of Medicine, Walter Reed Medical Center, Washington, DC. 2and Vascular Institute, Hendersonville, Tennessee; Capital
Cardiology Associates, Albany, New York; University of
Munich, Munich, Germany; Ottawa Heart Institute, On-
tario, Canada; Henry Ford Medical Center, Detroit, Mich-
igan; Yonsei Medical Center, Seoul, Korea, University
Hospital, Zurich, Switzerland; William Beaumont Hospi-
tal, Royal Oak, Michigan; Walter Reed Army Medical
Center, Washington, DC; and University Hospital of
Parma, Parma, Italy). Institutional review board approval
was obtained at each center. Individuals with known CAD,
as defined by prior myocardial infarction or coronary revas-
cularization, were excluded from the present study analysis.
All patients were in normal sinus rhythm and were
capable of the breath hold needed for CCTA. Patients with
heart rates 70 beats/min were given oral or intravenous
metoprolol as per local site protocol. All centers used
intravenous metoprolol at the time of CCTA performance
to lower heart rates below 70 beats/min. If the patient’s
heart rate did not drop below 70 beats/min, then CCTA
was performed at the lowest heart rate.
Before the initiation of the scan, we prospectively col-
lected information on the presence of categorical cardiac risk
factors in each individual. Systemic arterial hypertension
was defined as a documented history of high blood pressure
or treatment with antihypertensive medications. Diabetes
mellitus was defined by diagnosis of diabetes made previ-
ously by a physician and/or use of insulin or oral hypogly-
cemic agents. Dyslipidemia was defined as known but
untreated dyslipidemia or current treatment with lipid-
lowering medications. A positive smoking history was
defined as current smoking or cessation of smoking within
3 months of testing. Family history of coronary heart disease
was determined by patient query. Symptom presentation
was classified into 1 of 4 categories: typical chest pain,
atypical chest pain, noncardiac pain, or dyspnea (16).
Scan protocol and image reconstruction. The CCTA
scans were performed on a variety of different scanner
platforms (Lightspeed VCT, GE Healthcare, Milwaukee,
Wisconsin; Somatom Definition CT, Siemens, Erlangen,
Germany; Somatom Definition Flash CT, Siemens). Im-
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August 16, 2011:849–60 Age- and Sex-Related Prognosis by CCTAaging of a test bolus of contrast was performed at 2 mm
superior to the take-off of the left main coronary artery for
precise timing of contrast injection. During the CCTA
acquisition, 80 to 140 ml of iodinated contrast (Isovue 370,
Bracco Diagnostics, Princeton, New Jersey; Omnipaque,
GE Healthcare, Princeton, New Jersey; Visipaque, GE
Healthcare, Princeton, New Jersey; or Imeron 350; Bracco
Atlana Pharma, Konstanz, Germany) was injected, followed
by a 50-ml saline flush. Contrast timing was performed to
optimize uniform contrast enhancement of the coronary
arteries. The scan parameters were as follows: 64  0.625/
0.750-mm collimation, tube voltage 100 or 120 mV, effec-
tive 400 to 650 mA. Dose reduction strategies—including
electrocardiogram-gated tube current modulation, reduced
tube voltage, and prospective axial triggering—were used
whenever feasible. Estimated radiation dose for CCTA
ranged from 3 to 18 mSv.
Helical or axial scan data were obtained with retrospective
or prospective electrocardiogram gating, respectively. Im-
ages were reconstructed immediately after completion of the
scan to identify motion-free coronary artery images. Opti-
mal phase reconstruction was assessed by comparison of
different phases, if available, and the phase with the least
amount of coronary artery motion was chosen for analysis.
Multiple phases were utilized for image interpretation if
minimal coronary artery motion was different for different
arteries. CCTAs were evaluated by an array of post-
processing imaging techniques, including axial, multiplanar
reformat, maximum-intensity projection, and short-axis
cross-sectional views. In all individuals, irrespective of
image quality, every arterial segment was scored in an
intent-to-diagnose fashion. If a coronary artery segment was
uninterpretable despite these multiple techniques, the non-
evaluable segment was scored similarly to the most proximal
segment that was evaluable.
Noninvasive coronary artery analysis by CCTA. All
scans were analyzed by Level III–equivalent cardiologists
with experience interpreting several thousand CCTA scans.
Interpretation of CCTA was uniform across all study sites,
with coronary segments visually scored for the presence of
coronary plaque using a 16-segment coronary artery model
in an intent-to-diagnose fashion. In each coronary artery
segment, coronary atherosclerosis was defined as tissue
structures 1 mm2 that existed either within the coronary
rtery lumen or adjacent to the coronary artery lumen that
ould be discriminated from surrounding pericardial tissue,
picardial fat, or the vessel lumen itself. Coronary athero-
clerotic lesions were quantified for stenosis by visual esti-
ation. Luminal-diameter stenosis severity was scored as
one (0% luminal stenosis), mild (1% to 49% luminal
tenosis), moderate (50% to 69% luminal stenosis), or severe
70% luminal stenosis). Percent obstruction of coronary
rtery lumen was based on a comparison of the luminal
iameter of the segment exhibiting obstruction to the
uminal diameter of the most normal-appearing site imme-
iately proximal to the plaque. In instances in which plaque Nas highly calcified, 2-dimensional oblique images were also
isualized without maximal-intensity projection (i.e., 0.625-
o 0.75-mm isotropic voxel resolution) or multiplanar re-
ormats with cross-sectional views to minimize partial-
olume averaging artifact of calcium.
Plaque severity was graded on a per-patient, per-vessel,
nd per-segment level. Per-patient maximal plaque severity
as defined by the maximal intraluminal stenosis in any of
he coronary segments at the 50% stenosis or 70%
tenosis threshold.
For purposes of classification for per-vessel analyses, we
onsidered 4 arterial territories: left main artery (LM), left
nterior descending artery (LAD), left circumflex artery
LCx), and right coronary artery (RCA). Obstructive CAD
n the diagonal branches, obtuse marginal branches, and
osterolateral branches was considered as part of the LAD,
Cx, and RCA system, respectively. The posterior descend-
ng artery was considered as part of the RCA or LCx
ystem, depending on the coronary artery dominance. A
50% stenosis in the LM was considered obstructive in all
odels. Per-vessel CAD severity was defined by 50%
tenosis or 70% stenosis in 0, 1, 2, or 3 coronary artery
essels.
Per-segment analysis was judged for individual coro-
ary artery segments that included a 16-segment model,
s we have previously described (4). Similarly, the incre-
ental hazards of CAD for increasing numbers of
egments were calculated as clinical coronary artery
laque scores, as we have previously described (4). A
egment involvement score was calculated as the total
umber of coronary artery segments exhibiting plaque,
rrespective of the degree of luminal stenosis within each
egment (minimum  0; maximum  16). A segment
tenosis score was used as a measure of overall coronary
rtery plaque extent. Each individual coronary segment
as graded as having no to severe plaque (i.e., scores from
to 3) based on extent of obstruction of coronary luminal
iameter. Then the extent scores of all 16 individual
egments were summed to yield a total score ranging
rom 0 to 48. We further examined risk in association
ith any severe proximal stenosis in the LAD, LCx, or
CA vessels. Finally, we examined risk for any plaque
ithin the LM.
ollow-up. The primary endpoint was time to death from
ll causes. Follow-up procedures were approved by all study
enters’ institutional review boards. Death status for non-
.S. centers was gathered by clinical visits, telephone
ontacts, and questionnaires sent by mail, with verification
f all reported events by hospital records or direct contact
ith a patient’s attending physician. Death status for U.S.
enters was ascertained either by query of the Social Security
eath Index or by scripted interview by experienced physi-
ian and/or nurse study investigators.
tatistical analysis. SPSS version 12.0 (SPSS Inc., Chi-
ago, Illinois) and SAS version 9.2 (SAS Institute, Cary,
orth Carolina) were used for all statistical analyses.
c
a
v
w
a
a
i
b
a
A
i
r
l
c
R
C
2
t
p
r
fi
w
 per
852 Min et al. JACC Vol. 58, No. 8, 2011
Age- and Sex-Related Prognosis by CCTA August 16, 2011:849–60Categorical variables are presented as frequencies and
continuous variables as mean  SD. Variables were
ompared with chi-square statistic for categorical vari-
bles and by Student unpaired t test for continuous
ariables. Time to death from all causes and death rates
ere calculated using univariable Cox proportional haz-
rds models. In each case, the proportional hazards
ssumption was met. Adjusted models were also devised
ncluding multivariable stepwise models adjusting for
aseline demographics, cardiac risk factors, typicality of
ngina, and pre-test likelihood of obstructive CAD.
djusted models were also developed to test first-order
nteractions related to age, sex, and study site. A hazard
Demographics of the Entire Registry and StudyTable 1 Demographics of the Entire Registr
Entire Registry
(n  27,125)
Age, yrs 58 13
Male 14,997 (55)
Diabetes 4,067 (15)
Family history of premature CAD 9,849 (37)
Hyperlipidemia 14,906 (56)
Hypertension 13,582 (51)
Current smoker 4,994 (19)
History of PAD/CVD 485 (4)
Chest pain†
Typical angina 3,556 (16)
Atypical angina 8,860 (39)
Noncardiac 2,699 (12)
Asymptomatic 7,796 (34)
Pre-test CAD likelihood†
Low 6,477 (28)
Intermediate 14,137 (62)
High 2,153 (9)
Values are mean  SD or n (%). *p value for differences in percenta
pre-test likelihood of CAD missing in 518 patients.
CAD  coronary artery disease; CVD  cardiovascular disease; PAD
Clinical Characteristics of Study Group Stratified by Normal, NonobTable 2 Clinical Characteristics of Study Group Stratified by No
Normal
(n  10,146)
N
Male 4,528 (44.73)
Diabetes 985 (9.80)
Hypertension 4,187 (41.75)
Dyslipidemia 4,611 (45.99)
Family history of premature CAD 3,417 (34.330
Current smoking 1,742 (17.34)
Chest pain typicality*
Typical 1,332 (14.17)
Atypical 4,236 (45.05)
Noncardiac 1,059 (11.26)
Asymptomatic 2,776 (29.52)
Pre-test CAD likelihood
Low 3,249 (34.78)
Intermediate 5,618 (60.14)
High 474 (5.07)Values are n (%). *Chest pain typicality and pre-test likelihood of CAD missing in 2,867 patients.
CAD  coronary artery disease; CCTA  coronary computed tomography angiography.atio (HR) and 95% confidence interval (CI) were calcu-
ated from the Cox models. A 2-tailed p  0.05 was
onsidered statistically significant.
esults
linical characteristics of the study cohort. Amongst
7,125 consecutive patients undergoing CCTA at 12 cen-
ers for whom per-segment CAD data were available, 2,350
atients with a history of myocardial infarction, coronary
evascularization, and cardiac transplant were excluded. The
nal analysis cohort consisted of 24,775 patients. Follow-up
as obtained for 23,854 patients (96.3%), with 921 patients
rtStudy Cohort
tudy Cohort
n  23,854)
Excluded Patients
(n  3,271) p Value
57 13 60 13 0.0001
12,922 (54) 2,075 (64) 0.0001
3,451 (15) 616 (19) 0.0002
8,624 (37) 1,225 (38) 0.1614
12,807 (54) 2,099 (64) 0.0001
11,646 (49) 1,936 (59) 0.0001
4,251 (18) 743 (23) 0.0001
369 (4) 116 (8) 0.0001
0.0001
3,152 (15) 404 (21)
8.343 (40) 517 (27)
2,483 (12) 216 (11)
7,009 (33) 787 (41)
0.0001
6,060 (29) 417 (22)
12,978 (62) 1,159 (61)
1,824 (9) 329 (17)
study cohort versus excluded patients. †Typicality of chest pain and
ipheral arterial disease.
tive, and Obstructive CAD by CCTA, Nonobstructive, and Obstructive CAD by CCTA
ructive CAD
8,114)
Obstructive CAD
(n  5,594) p Value for Trend
9 (60.00) 3,545 (63.70) 0.0001
2 (14.94) 1,264 (22.79) 0.0001
9 (51.81) 3,320 (59.98) 0.0001
7 (57.84) 3,549 (64.03) 0.0001
0 (35.32) 2,397 (43.53) 0.0001
9 (15.83) 1,240 (22.35) 0.0001
0.0001
0 (12.01) 1,000 (21.03)
2 (36.78) 1,595 (33.55)
3 (10.73) 691 (14.54)
5 (40.48) 1,468 (30.88)
0.0001
3 (28.31) 888 (18.78)
3 (63.21) 3,067 (64.86)
6 (8.48) 774 (16.37)Cohoy and
S
(
ges forstrucrmal
onobst
(n 
4,84
1,20
4,13
4,64
2,81
1,26
82
2,51
73
2,76
1,92
4,29
57
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August 16, 2011:849–60 Age- and Sex-Related Prognosis by CCTAlost to follow-up. The study cohort was middle-aged (age
57  13 years, 54% male) with a high prevalence of
cardiovascular risk factors and symptoms. They presented
with typical or atypical angina in the majority of cases, with
the majority of individuals having intermediate or high
pre-test likelihood of obstructive CAD. Excluded patients
had a higher pre-test likelihood of CAD (Table 1).
Clinical characteristics associated with CAD and mortality.
Survival was examined after a mean follow-up of 2.3  1.1
years (median 2.1 years; interquartile range: 1.5 to 3.1
years), at which point 404 deaths were recorded. Increasing
severity of CAD was associated with male sex, diabetes,
hypertension, dyslipidemia, family history of CAD, current
smoking, typical angina, and high pre-test likelihood of
CAD (p  0.0001 for all) (Table 2). In univariable Cox
proportional hazards models, increased hazard for death was
associated with advanced age, diabetes, hypertension, un-
treated dyslipidemia, and current smoking, but not family
history of CAD or pre-test CAD likelihood (Table 3).
Clinical Characteristics Associated With MortalityTable 3 Clinical Characteristics Associated With Mortality
Variable Univariate HR (95% CI) p Value
Age 1.09 (1.08–1.10) 0.0001
Male 1.05 (0.87–1.28) 0.6021
Diabetes 2.13 (1.71–2.65) 0.0001
Hypertension 1.93 (1.57–2.37) 0.0001
Hyperlipidemia 0.71 (0.59–0.87) 0.0007
Current smoking 1.47 (1.17–1.85) 0.0009
Family history of premature CAD 1.11 (0.90–1.36) 0.3401
Pre-test CAD likelihood 1.20 (0.996–1.45) 0.0547
CAD  coronary artery disease; CI  confidence interval; HR  hazard ratio.
Coronary Artery Stenosis Severity by Segment For Individuals WhoTable 4 Coronary Artery Stenosis Severity by Segment For Indi
Coronary Segment
Alive (n  23,450)
n % With CAD Stenosis Score
LM 3,257 14 0.16 0.43
LAD
Proximal 9,539 41 0.55 0.76
Mid 7,407 33 0.49 0.80
Distal 1,811 9 0.12 0.43
Diagonal artery 1 2,560 12 0.18 0.55
Diagonal artery 2 799 5 0.08 0.35
LCx
Proximal 4,459 20 0.26 0.59
Distal 1,763 9 0.12 0.45
Obtuse marginal 1 1,768 8 0.12 0.47
Obtuse marginal 2 468 5 0.08 0.37
Right coronary artery
Proximal 5,424 24 0.32 0.65
Mid 4,157 19 0.27 0.65
Distal 2,159 11 0.15 0.48
Right PL artery 123 1 0.02 0.18
Left PL artery 277 2 0.03 0.25
Posterior descending artery 956 5 0.07 0.35CAD  coronary artery disease; LAD  left anterior descending artery; LCx  left circumflex artery; LM CCTA findings among those who lived versus died. As
compared with patients who were alive at follow-up, pa-
tients who died had significantly more severe coronary artery
stenoses in the majority of coronary segments (Table 4).
Impact of per-patient, per-vessel, and per-segment CAD
severity by CCTA on death from all causes. In both
univariable as well as multivariable Cox regression anal-
ysis considering age and CAD risk factors, all-cause
mortality was predicted by maximal per-patient nonob-
structive and obstructive CAD, whether using a defini-
tion of obstructive CAD as 1% to 49% or 1% to 69%
stenosis (Table 5, Fig. 1).
By both univariable and multivariable Cox models, per-
vessel assessment of obstructive CAD demonstrated a dose-
response relationship for increased hazards for death for
1-vessel, 2-vessel, 3-vessel, or LM CAD (Table 5, Fig. 2).
Similarly, in both univariable and multivariable Cox regres-
sion analysis, on a per-segment basis, higher rates of
mortality were associated with greater numbers of segments
with plaque, with stenosis-adjusted segments with plaque,
with any severe proximal stenosis, and with any plaque
within the LM (Table 5).
Sixty-six deaths (0.65%) occurred in patients without
evident CAD by CCTA (n  10,146; 43%), resulting in a
mean annualized death rate of 0.28%. In additional analyses
of patients undergoing CCTA followed for 4 years (n 
1,816) without evidence by CCTA (n  1,009), annualized
death rates were 0.22%.
Age- and sex-stratified impact of CCTA-visualized CAD
on death from all causes. Individuals65 years of age had
lower pre-test probability of CAD than those 65 years of
Versus Diedls Who Lived Versus Died
Dead (n  404) p Value
% With CAD Stenosis Score Stenosis Score % With CAD
7 27 0.34 0.61 0.0001 0.0001
9 68 1.11 1.00 0.0001 0.0001
5 51 0.90 1.06 0.0001 0.0001
9 18 0.24 0.60 0.0001 0.001
7 22 0.37 0.81 0.0001 0.0001
5 8 0.16 0.59 0.0016 0.1034
8 41 0.65 0.94 0.0001 0.0001
6 21 0.33 0.74 0.0001 0.0001
5 16 0.29 0.74 0.0001 0.0001
6 12 0.19 0.60 0.0002 0.0012
1 48 0.78 0.99 0.0001 0.0001
3 40 0.66 0.96 0.0001 0.0001
1 21 0.27 0.62 0.0001 0.0001
5 8 0.10 0.35 0.0006 0.0001
9 5 0.05 0.22 0.4342 0.0389
8 14 0.23 0.63 0.0001 0.0001Livedvidua
n
10
25
19
5
7
1
15
6
5
1
18
14
6
4left main artery; PL  posterolateral.
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Age- and Sex-Related Prognosis by CCTA August 16, 2011:849–60age (pre-test probability low 34% vs. 16%; intermediate 60%
vs. 67%, high 6% vs. 17%, chi-square p  0.0001). As
compared with individuals without CAD within respective
age groups, patients 65 years of age experienced higher
Univariable and Adjusted Hazard Ratios for All-Cause Mortality by PPer-Vessel, Per-Segment Analysis by Obstructiv CAD at the 5Table 5 Univariabl and Adjusted Hazard Ratio for All-Caus MPer-Vessel, and Per-Segment Analysis by Obstructive C
CCTA Result
Obstructive CAD (Defined at 50% L
Univariable HR
(95% CI) p Value
Risk-Adjuste
(95% CI)
Per-patient analysis
Normal 1.00 Reference 1.00
Nonobstructive CAD 2.88 (2.15–3.86) 0.0001 1.60 (1.18–2
Obstructive CAD 6.05 (4.58–7.99) 0.0001 2.60 (1.94–3
Per-vessel analysis
Normal 1.00 Reference 1.00
Nonobstructive 2.88 (2.15–3.86) 0.0001 1.62 (1.20–2
1-vessel obstructive 4.12 (2.96–5.72) 0.0001 2.00 (1.43–2
2-vessel obstructive 6.93 (4.82–9.96) 0.0001 2.92 (2.00–4
3-vessel or left main
obstructive
10.52 (7.50–14.7) 0.0001 3.70 (2.58–5
Per-segment analysis
Segment involvement score
(per segment involved)
1.22 (1.18–1.25) 0.0001 1.10 (1.06–1
Segment stenosis score (per
segment severity)
1.12 (1.11–1.14) 0.0001 1.06 (1.05–1
Any severe proximal stenosis 4.01 (3.12–5.17) 0.0001 2.15 (1.66–2
Any left main stenosis 2.51 (2.01–3.13) 0.0001 1.45 (1.15–1
NA  not applicable; other abbreviations as in Table 3.
Figure 1 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by
of None, Nonobstructive, and Obstructive CAD
Patients with nonobstructive coronary artery disease (CAD) had an intermediate prognhazards for mortality if 2- or 3-vessel/LM obstructive CAD
was present than patients 65 years of age, with similar
rates of death for nonobstructive and 1-vessel obstructive
CAD (Table 6, Fig. 3).
tient,nd 70% Stenosis Levellity by Per-Patient,
t the 50% and 70% Stenosis Level
Obstructive CAD (Defined at 70% Level)
p Value
Univariable HR
(95% CI) p Value
Risk-Adjusted HR
(95% CI) p Value
Reference 1.00 Reference 1.00 Reference
0.0023 3.29 (2.50–4.34) 0.0001 1.76 (1.32–2.34) 0.0001
0.0001 8.11 (6.00–11.0) 0.0001 3.13 (2.27–4.31) 0.0001
Reference 1.00 Reference 1.00 Reference
0.0018 3.30 (2.50–4.34) 0.0001 1.77 (1.33–2.36) 0.0001
0.0001 5.67 (3.97–8.10) 0.0001 2.35 (1.62–3.42) 0.0001
0.0001 11.40 (7.56–17.2) 0.0001 3.94 (2.57–6.04) 0.0001
0.0001 15.52 (10.1–23.9) 0.0001 5.27 (3.36–8.27) 0.0001
0.0001 NA NA NA NA
0.0001 NA NA NA NA
0.0001 NA NA NA NA
0.0015 NA NA NA NA
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August 16, 2011:849–60 Age- and Sex-Related Prognosis by CCTAFemale patients referred to CCTA had higher pre-test
probability of CAD than men. Differences in pre-test
likelihood for obstructive CAD existed by sex, with male
and female patients presenting with low (pre-test probabil-
ity low 35% vs. 24%, intermediate 56% vs. 68%, and high
9% vs. 9%; p  0.0001). As compared with individuals
without CAD within respective sexes, women experienced
higher hazards for mortality for 3-vessel or LM obstructive
CAD than males, with similar rates of death for nonob-
structive, 1-vessel, and 2-vessel obstructive CAD (Table 7,
Fig. 4).
When stratified by both age and sex, differences in
multivariable risk-adjusted hazards for mortality were ob-
served for nonobstructive and 1-, 2-, and 3-vessel or LM
obstructive CAD (Table 8). Tests for interactions of age
Figure 2 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by
Note the dose-response relationship of mortality to increasing numbers of vessels
CCTA  coronary computed tomography angiography.
Adjusted Hazard Ratios for All-Cause Mortalityfor Patients <65 Versus >65 Years of AgeTable 6 Adjust d Hazard Ratio for All-Causfor Patients <65 Versus >65 Years
Variable
Age
HR 95%
Normal 1 Refer
Nonobstructive 1.57 0.98–
1-vessel disease 2.12 1.22–
2-vessel disease 4.00 2.16–
3-vessel disease or left main disease 6.19 3.43–Abbreviations as in Table 3.and CAD (p  0.21) and sex and CAD (p  0.76) did not
reveal significant relationships.
Discussion
These results of the CONFIRM registry represent the first
prospective international multicenter data to relate CCTA-
determined extent and severity of CAD to all-cause mor-
tality and demonstrate the independent prognostic value of
both obstructive as well as nonobstructive CAD by CCTA.
Importantly, this study had adequate sample size and was
adequately powered (beta 0.90, alpha 0.001) to permit
differential risk stratification of individuals as categorized by
age group and sex. The findings of this study should be
considered widely generalizable, given the high number of
resence, Extent, and Severity of CAD by CCTA
bstructive coronary artery disease (CAD).
rtality
ge
Yrs Age >65 Yrs
p Value HR 95% CI p Value
Reference 1 Reference Reference
0.0594 1.63 1.08–2.47 0.0212
0.0080 1.96 1.25–3.07 0.0036
0.0001 2.46 1.51–4.02 0.0003
0.0001 3.10 1.95–4.92 0.0001the P
with oe Mo
of A
<65
CI
ence
2.51
3.69
7.40
11.2
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Age- and Sex-Related Prognosis by CCTA August 16, 2011:849–60Figure 3 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by Presence, Extent, and Severity of CAD
by CCTA as Stratified by Age <65 or >65 Years
Although rates of mortality in relationship to CAD extent are lower in patients age 65 years (A), patients age 65 years with 2- and 3-vessel CAD experience a higher
relative rate of mortality referenced to patients age 65 years with no CAD in comparison with patients age 65 years with 2- and 3-vessel CAD referenced to patients
age 65 years with no CAD (B). Abbreviations as in Figure 2.
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August 16, 2011:849–60 Age- and Sex-Related Prognosis by CCTAenrolled subjects; the inclusion of numerous clinical sites
within North America, Europe, and Asia; and the unifor-
mity of study results across sites.
Despite increasing adoption of CCTA for clinical use in
individuals with suspected CAD, limited “real world” effec-
tiveness evidence still exists to support the prognostic
significance of CAD findings as detected by current-
generation 64-detector row CCTA. Furthermore, prior
studies to date that have examined the ability of CCTA
findings to stratify risk have been generally limited to single
centers with relatively small sample sizes. We previously
reported the predictive value of CCTA measures of CAD
extent and severity in a 2-center study of 5,330 consecutive
patients, but data were limited in that population to vessel-
based analyses, and the prognostic potential of segment-
based as well as nonobstructive CAD detection by CCTA
could not be examined (5). In a separate analysis, we
reported the prognostic significance of CCTA-identified
CAD findings in 1,256 consecutive patients with suspected
CAD for the prediction of major adverse cardiac events (8).
Although we noted a 16- to 17-fold increased risk in
myocardial events in patients with obstructive CAD, the
observed event rates were low (0.6% to 1.8%) and the
follow-up duration shorter than in the present study. In this
regard, the current data extend prior studies by examining
CCTA findings of CAD in a large consecutive cohort
comprising multiple international sites that was evaluated by
current-generation computed tomography (CT) technology
for measures of both obstructive and nonobstructive CAD.
That CCTA can effectively risk stratify individuals without
known CAD should be invaluable for guiding the develop-
ment of clinical practice guidelines and appropriate use
criteria.
One notable finding in our study was that although the
pre-test likelihood of obstructive CAD—as estimated by
the Diamond-Forrester (D-F) tabular method—was highly
predictive of the presence of obstructive CAD by CCTA, it
did not demonstrate predictive value for incident death in
this large cohort of patients with suspected CAD. At
present, clinicians commonly use D-F pre-test estimations
of likelihood of obstructive CAD as a metric to determine
whether patients would benefit from noninvasive testing.
Because global clinical risk scores are currently lacking for
symptomatic stable individuals with suspected CAD, many
Adjusted Hazard Ratios for All-Cause Mortality fTable 7 Adjusted Hazard Ratios for All-Caus
CAD Severity
Female
HR 95% CI
Normal 1.00 Reference
Nonobstructive 1.67 1.10–2.54
1-vessel disease 1.83 1.11–3.01
2-vessel disease 2.88 1.63–5.07
3-vessel/left main disease 4.21 2.47–7.18
Abbreviations as in Table 3.have also adopted use of the D-F method for “risk”assessment (17,18). The current data suggest that use of the
D-F method is insufficient for this purpose and should not
be used solely as a judge of risk.
We also identified a utility of nonobstructive CAD
detection for risk stratification of individuals at height-
ened risk of incident death. Indeed, individuals with
nonobstructive CAD (HR: 1.62; 95% CI: 1.08 to 2.43)
by CCTA experienced a mortality risk that was similar to
that of those with obstructive 1-vessel CAD (HR: 1.75;
95% CI: 1.12 to 2.72). These data corroborate our prior
studies using older generation electron beam CT tech-
nology, where the presence of nonobstructive CAD
conferred similar risk as 1-vessel obstructive CAD. These
findings have important implications, as patients with
nonobstructive CAD comprise the majority of patients
who experience myocardial events and for whom func-
tional stress testing aimed at detecting flow-limiting
coronary artery stenoses would be expectedly negative
(19). Given a robust evidence base demonstrating the
highly salutatory effect of primary prevention of CAD
events in at-risk individuals, future studies should be
performed to determine the effect of aggressive medical
therapy and lifestyle modification for individuals with
CCTA-identified nonobstructive CAD.
We recently reported the results of an exploratory
analysis of 1,127 consecutive patients with suspected
CAD undergoing 16-detector row CCTA identified to
have only obstructive CAD. In this study, 490 patients
were identified as having nonobstructive CAD (as de-
fined by maximal 50% luminal diameter stenosis at the
per-patient level) (15). In 4-year follow-up, the number
of coronary segments exhibiting nonobstructive CAD
was predictive of incident death in women but not in
men. This study expands on these prior published results
by using a study cohort of sufficient magnitude to
examine the presence of nonobstructive CAD at the
per-patient level. The present data corroborate the prior
data, revealing a prognostic value for per-patient nonob-
structive CAD detection in women but not in men.
Further, the current study extends prior study results by
demonstration that 1-vessel obstructive CAD also con-
fers heightened risk of death in women but not in men.
Numerous possibilities exist to explain these findings.
Women in our study had lower rates of both obstructive
male Versus Male Patientsrtality for Female Versus Male Patients
Male
p Value HR 95% CI p Value
eference 1 Reference Reference
0.0160 1.52 0.97–2.40 0.0689
0.0176 2.05 1.25–3.35 0.0043
0.0003 2.81 1.65–4.77 0.0001
0.0001 3.27 1.96–5.45 0.0001or Fee Mo
Rand nonobstructive CAD in contrast to their male
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ity. This generally lower prevalence of disease in women
has been historically associated with lower rates of
Figure 4 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by
Although rates of mortality in relationship to CAD extent are lower in women, wom
women with no CAD (A) in comparison with men with 3-vessel CAD referenced toinvasive coronary angiographic evaluation and often leadsto “exclusion” of cardiac causes of symptoms in women,
despite a higher rate of hospitalization for angina as
compared with men (20,21). It remains possible in this
ence, Extent, and Severity of CAD by CCTA as Stratified by Sex
h 3-vessel CAD experience a higher relative rate of mortality referenced to
ith no CAD (B). Abbreviations as in Figure 2.Pres
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noncardiac diagnoses for symptoms, and lack of aggressive
treatment for these CAD findings resulted in heightened risk of
incident death. Future studies should carefully evaluate this
potential explanation and should determine the effect of
primary prevention with aggressive medical therapy in this
cohort.
In the present study, we also observed differential risk
stratification of CCTA-identified CAD findings by age
groups. Although risk of all-cause death increased in a
generally linear fashion for patients 65 years of age for
extent and severity of CAD, patients 65 years of age
experienced a more abrupt increase in risk of death associ-
ated with 2- and 3-vessel or LM CAD over nonobstructive
or 1-vessel CAD. Although numerous explanations exist to
account for these findings, it may be that younger patients
with greater extent and severity of CAD represent a cohort
with more aggressive forms of atherosclerosis than their
older counterparts, thus resulting in a higher risk than for
older patients with more insidious atherosclerosis.
Finally, we observed a very low rate of death for individuals
without evident CAD by CCTA. This low rate of death
validates the favorable prognosis that has been uniformly
observed in prior smaller registries and emphasizes a clinical
value of CCTA for identification of individuals in whom no
further additional testing and/or therapy is necessary or indi-
cated (4–14). Using older generation electron beam CT
technology, Ostrom et al. (22) demonstrated that this very low
death rate continues to persist for up to 7 years from the time
of the CCTA, and the present results are in direct accordance
with those findings. Similarly, the long-term4-year progno-
is of patients in the present registry without evident CAD by
CTA was extremely favorable, with a 0.22% annualized
eath rate. These results may inform clinicians on the need for
epeat testing in patients with normal CCTA and suggest a
warranty” period of a normal CCTA to last at least 4 years.
tudy limitations. Although this study addresses many of
he shortcomings of prior analyses examining the prognostic
alue of CCTA, it is not without limitations. For the present
nalysis, the major endpoint was all-cause mortality. Other
softer” endpoints—including myocardial infarction, unstable
ngina, or CAD-related hospitalization—were not included in
his initial analysis. Although use of all-cause death mitigates
Multivariable Adjusted Hazard Ratios for All-Cause Mortality as StrTable 8 Multivariable Adjusted Hazard Ratios for All-Cause Mo
CAD Severity
Age <65 Yrs
Male Fe
HR 95% CI HR
Normal 0.70 0.36–1.36 1.00
Nonobstructive 1.65 0.93–2.91 1.59
1-vessel disease 2.46 1.26–4.82 2.23
2-vessel disease 4.16 1.97–8.82 6.59
3-vessel/left main disease 6.80 3.35–13.8 10.59
Abbreviations as in Table 3.scertainment bias, it will nevertheless be important to performfuture studies examining the risk of major adverse cardiac
events in relation to CCTA findings. Further, referral bias due
to excluded patients and treatment of individuals based on
CCTA findings of CAD are unknown in this open-label
multicenter registry. Whether percutaneous or surgical coro-
nary revascularization, enhanced medical therapy, or lifestyle
modifications occurred after CCTA performance is unknown.
We have previously demonstrated that CAD risk factor control
is improved in direct relation to the extent and severity of
CCTA CAD findings, but whether this affects mortality has
not been explored. For proper evaluation of this issue, large-
scale trials with prescribed treatment algorithms will be neces-
sary. In addition, our analysis entailed the evaluation of CAD
by semiquantitative visual analysis rather than by volumetric
quantification of plaque. At the time of initiation of the study
(and to date), no automated validated software existed for
automatic quantification of plaque or stenosis severity. Instead,
this multicenter study used experienced level III CCTA
imagers and used a uniform grading system that is most
commonly used in daily clinical practice. Finally, this study
examined only patients without history of known CAD. As
such, whether these findings can be extrapolated to those with
prior myocardial infarction or coronary revascularization needs
to be tested in future studies.
Conclusions
In the large, prospective, international, multicenter CONFIRM
registry, extent and severity of CAD by CCTA successfully
identifies individuals at heightened risk for all-cause mor-
tality. Presence of both obstructive and nonobstructive
CAD by CCTA on a per-patient, per-vessel, and per-
segment basis portends worsened prognosis, with differen-
tial risk noted between sex and age groups. Importantly,
individuals without evident CAD by CCTA are at very low
risk of death.
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